← Eichor
Condition: Nsclc Stage Iiia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Nsclc Stage Iiia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Can
Phase 3 · 49 location(s) · Dizal (Jiangsu) Pharmaceutical Co., Ltd. · NCT07182682ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06426511Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After R
Phase N/A · 1 location(s) · Liaoning Cancer Hospital & Institute · NCT06109454Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Phase N/A · 22 location(s) · Fundación GECP · NCT06634199Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Phase 2 · 5 location(s) · University Hospital, Bonn · NCT06810609Pathological Response After Neoadjuvant Treatment on NSCLC
Phase N/A · 17 location(s) · Fundación GECP · NCT05167487A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT07428044Using Urine Samples to Identify Lung Cancer
Phase N/A · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06033248D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage II
Phase 3 · 1 location(s) · Guangdong Provincial People's Hospital · NCT07016126A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT05732974To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mut
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT04853342Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung
Phase 3 · 1151 location(s) · National Cancer Institute (NCI) · NCT04267848Molecular Signature From Tumor to Lymph Nodes
Phase N/A · 12 location(s) · Assistance Publique - Hôpitaux de Paris · NCT04677205An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · ToLymph Inc. · NCT06693336Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lu
Phase 2 · 21 location(s) · Fundación GECP · NCT07153445Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Phase 2 · 1 location(s) · University Hospital Heidelberg · NCT04865250A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants
Phase 1 · 1 location(s) · Bio-Thera Solutions · NCT07180862Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Phase 3 · 33 location(s) · Nuvation Bio Inc. · NCT07154706Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05010109Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Phase 1 · 2 location(s) · Ohio State University Comprehensive Cancer Center · NCT05136846Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04892953Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Phase 2 · 3 location(s) · Jianxing He · NCT07492342Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of
NA · 1 location(s) · Northwestern University · NCT05802186A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed No
Phase 3 · 35 location(s) · ETOP IBCSG Partners Foundation · NCT06931717Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · 382 location(s) · Alliance for Clinical Trials in Oncology · NCT06632327Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT05241028Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
Phase 2 · 1 location(s) · Fudan University · NCT07398937Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · 266 location(s) · National Cancer Institute (NCI) · NCT06498635The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT05798845To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Posi
Phase 2 · 1 location(s) · Juan LI, MD · NCT06192849
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.